Notice of Effectiveness · EFFECT
CytoDyn, Inc.
CYDYOTCEQUITYCurrent
Notice of Effectiveness
Structured filing — EFFECT
primary_doc.xml
Notice details
- Submission type
- EFFECT
- Act
- 33
Effectiveness
- Effective date
- 2026-10-07
- Effective time (as filed)
- 12:00:00
- Form
- S-3
Registrant 1
- Registrant
- CytoDyn Inc.
- Registrant CIK
- 0001175680
- File number
- 333-299150
Company context
CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.